Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S.

SHANGHAI, Oct. 11, 2019 /PRNewswire/ -- Kangpu Biopharmaceuticals announced today that it has successfully completed a first-in-human phase I single ascending dose (SAD) clinical study of KPG-818 conducted inthe United States. This randomized, double-blind, placebo-controlled study evaluated the...

2019-10-11 13:00 449

I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5

SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases, today announced that its I...

2019-10-04 13:40 570

Medicago's New Drug Submission accepted for scientific review by Health Canada: An important step for Medicago towards commercialization of its innovative influenza vaccine

QUEBEC CITY, Oct. 3, 2019 /PRNewswire/ -- Medicago, a biotechnology company and global leader in the development and production of plant-derived vaccines with headquarters inQuebec City, announces today that Health Canada accepted for scientific review its New Drug Submission (NDS) for a plant-ba...

2019-10-03 06:30 414

Mayne Pharma Signs 20-Year Exclusive License and Supply Agreement for Novel Oral Contraceptive in the US

ADELAIDE, Australia, Oct. 2, 2019 * Mayne Pharma Group Limited (Mayne Pharma or Company) (ASX: MYX) has signed a 20‑year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to commercialise a novel oral contraceptive comprising Estetrol (E4), and drospirenone, (E4/...

2019-10-02 12:01 7560

Shanghai Pharma Global Standard Stock Incentive Scheme to Push Innovation Refiled for Approval

SHANGHAI, Sept. 30, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) (Hong Kong Stock Exchange: 2607) (Shanghai Stock Exchange: 601607) has launched a new stock incentive plan (the Plan) aligned with international standards aimed at retaining and attracting talent...

2019-10-01 04:00 7044

Yuyu Pharma Unveils New Corporate Logo

SEOUL, South Korea, Sept. 30, 2019 /PRNewswire/ -- Yuyu's corporate logo was first created in 1941 to honor the company's proud history and highlight Yuyu's image as a company on the cutting-edge of the industry.  Yuyu Pharma ...

2019-09-30 21:00 311

Ascletis Announces Departure of Chief Financial Officer

HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...

2019-09-30 16:30 263

Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019

NORTH BRUNSWICK, New Jersey, Sept. 30, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye" or "the Company"), a global clinical-stage biopharmaceutical company dedicated to discovery, development and commercialization of new and effective drugs with a focus on Oncology, announced today at the ...

2019-09-30 13:41 233

The 10th China (Taizhou) International Medical Expo successfully ended

NANJING, China, Sept. 30, 2019 /PRNewswire/ -- From September 18 to 20, the 10th China (Taizhou) International Medical Expo was held in China Medical City (CMS), according toChina (Taizhou) Medical Expo News Center.

2019-09-30 13:27 263

Bridge Biotherapeutics Presents Positive Results from Phase 1 Clinical Study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) Treatments at the ERS International Congress 2019

* The study results presented at the ERS 2019 as a late breaking abstract demonstrated positive safety and tolerance in healthy volunteers * Data demonstrated LPA inhibition of BBT-877 up to 90% in multiple-ascending dose cohorts SEONGNAM, South Korea and MADRID, Sept. 29, 2019 /PRNewswire/ --...

2019-09-30 06:00 330

Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal

MELBOURNE, Australia and SYDNEY, Sept. 29, 2019 /PRNewswire/ -- Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been awarded a major grant from the US National Institut...

2019-09-30 05:00 304

China Biologic Forms Special Committee to Review "Going Private" Proposal

BEIJING, Sept. 24, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that its board of directors (the "Board") has formed a special committee (th...

2019-09-24 20:00 11286

I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Multiple Cancer Types

SHANGHAI, Sept. 23, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focusing on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, today annou...

2019-09-23 19:00 872

CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency

SHANGHAI, Sept. 23, 2019 /PRNewswire/ -- CARsgen Therapeutics Inc., a clinical-stage biopharmaceutical company today announced the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) eligibility to its investigational CAR-T cell therapy fully human anti-BCMA (B Cell Maturation ...

2019-09-23 18:00 1835

Chipscreen Biosciences's Oringinal New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted

SHENZHEN, China, Sept. 19, 2019 /PRNewswire/ -- The new drug application (NDA) of Chiglitazar (Bilessglu®), an innovative new chemical entity (Category 1 c hemical drug) for type 2 diabetes discovered and developed by Shenzhen Chipscreen Biosciences (Stock Symbol: 688321.SH), has been accepted by ...

2019-09-19 23:02 1233

More than 800 pharmaceutical companies from 23 countries gathered in Taizhou, China -- the 10th China (Taizhou) International Medical Expo is about to open

NANJING, China, Sept. 19, 2019 /PRNewswire/ -- The 10th China (Taizhou) International Medical Expo, hosted by the Jiangsu Provincial People's Government and the Taizhou Municipal People's Government, is held inChina Taizhou Medical City fromSeptember 18 to 20.

2019-09-19 19:13 1276

China Biologic Announces Receipt of Preliminary Non-Binding "Going Private" Proposal

BEIJING, Sept. 18, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that its board of directors (the "Board") has received a preliminary non-bin...

2019-09-19 04:01 10438

Traditional Chinese Medicine Giant DEEJ Partners with 111 for Direct Sourcing

SHANGHAI, Sept. 12, 2019 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, today announced the signing of a strategic cooperation agreement with Dong-E-E-Jiao Co., Ltd. ("DEEJ") (SZ: 000423), a leading company principally...

2019-09-12 23:16 6729

Gracell Announces Interim Readout of Investigation for First-in-class FasT CAR-19 in patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and Extension in Use of FasT CAR to Other Immune Cell Programs

SUZHOU and SHANGHAI, China, Sept. 11, 2019  /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell therapy company, today announced a positive continued clinical readout of a multi-center pilot study designed to evaluate the safety and efficacy of Gracell's f...

2019-09-12 05:00 1498

China Pharma Holdings, Inc. Has Entered into A Memorandum of Understanding With World Health Advanced Technologies, Ltd.

HAIKOU CITY, China, Sept. 11, 2019 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," "CPHI", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that it has entered...

2019-09-11 20:00 6458
12345 ... 40